Publication | Open Access

A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)

UrologyGenitourinary CancerMedicineCancer TreatmentOncologyRadiation OncologyMolecular OncologyCediranib Versus Cediranib